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Abstract.  The two forms of clathrin light chains (LCA 
and LCB) or clathrin-associated proteins (CAP~ and 
CAP2) have presented an immunochemical paradox. 
Biochemically similar, both possess two known func- 
tional parameters: binding the clathrin heavy chain 
and mediating the action of an uncoating ATPase.  All 
previously reported anti-CAP mAbs, however,  react 
specifically with only CAP~ (Brodsky, E  M.,  1985, 
J.  Cell Biol.,  101:2047-2054;  Kirchhausen, T., S.  C. 
Harrison, P.  Parham, and E  M. Brodsky, 1983, Proc. 
Natl. Acad. Sci. USA, 80:2481-2485).  Four new anti- 
CAP mAbs are reported here: two, C-7H12 and C-6C1, 
react with both forms; two others, C-10B2 and C-4E5, 
react only with the lower form. Sandwich ELISAs in- 
dicated that C-10B2, C-4E5,  C-6C1,  and C-7H12 react 
with distinct epitopes. Monoclonal antibodies C-10B2 
and C-4E5  immunoprecipitate clathrin-coated vesicles 
(CCVs) and react with CAP2 epitopes accessible to 
chymotrypsin on the vesicle. These mAbs inhibit 
phosphorylation of CAP2 by endogenous CCV casein 
kinase II. In contrast, C-6C1  and C-7H12 react with 
epitopes that are relatively insensitive to chymotrypsin. 
CAP peptide fragments containing these epitopes 
remain bound to reassembled cages or CCVs after 
digestion. Immunoprecipitation and ELISAs demon- 
strate that C-7H12 and C-6C1  react with unbound 
CAPs but not with CAPs bound to triskelions or 
CCVs. The data indicate that the CAPs consist of at 
least two discernible structural domains: a noncon- 
served, accessible domain that is relevant to the phos- 
phorylation of CAP2 and a conserved, inaccessible do- 
main that mediates the binding of CAPs to CCVs. 
T 
HE cage structure  enclosing  clathrin-coated  vesicles 
(CCVs) ~  self-assembles from triskelions composed of 
the three clathrin heavy chain and three clathrin light 
chain molecules (also called clathrin-associated proteins or 
CAPs [5, 9]). Two forms of CAPs exist in cells of  higher ver- 
tebrates:  33-kD  (CAP2) and 36-kD  (CAP1) forms are ob- 
served in tissues of  neuronal origin, while analogous 28- and 
30-kD forms are observed in other tissues (4). The two forms 
isolated from brain tissue have several features in common, 
including the ability to bind calmodulin (9) and a single site 
on the clathrin heavy chain (14), an essential role in mediat- 
ing the action of an uncoating ATPase (11), and resistance to 
denaturation by heating (9), a property that facilitates their 
purification. The two forms are distinguishable by their mi- 
gration rates during SDS PAGE, their slightly different iso- 
electric points (5, 10), their differing immunological proper- 
ties  (6), and by the enhanced  ability of CAP2 to act as a 
substrate for phosphorylation under certain conditions (12). 
The production of mAbs reactive only with CAP1 (2, 6) 
provided evidence of the structural  diversity  of these two 
polypeptides. In this report,  mAbs reactive with CAP2 and 
with both CAP1 and CAP2 are presented,  and their charac- 
1. Abbreviations  used in this paper: CAP, clathrin-associated protein; CCV, 
clathrin-coated vesicle; CE common fragment; PVC, polyvinyl chloride. 
terization reveals that distinct epitopes are involved in medi- 
ating the functional parameters of CAPs. 
Materials and Methods 
Preparation of  Hybridomas 
Female BALB/c mice (6-8 wk of age) were initially immunized intraperi- 
toneally with 100 ~tg of CAPs purified by heating at 100°C  for 5 min as 
reported previously (9) and emulsified in complete Freund's adjuvant (day 
74). Mice were boosted intrapetitoneally on day 32 with 100 I~g of antigen 
emulsified in incomplete Freund's adjuvant. Mice were boosted a final time 
with intraperitoneal and intravenous injections of 50 gg of antigen on days 
4 and 3 before fusion on day  1. 
Sp 2/0-Ag14 myeloma cells were cultured in RPMI 1640 supplemented 
with 15% fetal calf serum, 1 mM L-glutamine, 1 mM sodium pyruvate, 100 
~tM minimal essential medium nonessential amino acids, minimal essential 
medium vitamin solution,  100 ~tM 8-azaguanine, and antibiotics. Spleen 
cells from immunized animals were fused at a 5:1 ratio to Sp 2/0-Ag14 my- 
eloma cells using deionized 44% polyethylene glycol 1,000 in RPMI 1640. 
Cells were plated into 96-well plates 24 h after fusion at a density of 104 
myeloma cells per well (200 Ixl) and selected by adding 15 I.tg/ml hypoxan- 
thine, 7.6 I~g/ml thymidine, and 0.18 lxg/ml aminopterin. This procedure 
usually yields at least one clone per well by the end of 10 d. Clones were 
passed to  1-ml wells before screening. 
Hybridoma supernatants were screened by an ELISA. Briefly,  antigens 
were coated onto polyvinyl chloride (PVC) plates (Linbro, Flow Laborato- 
ties, Hamden, CT) at a concentration of 5 I.tg/ml in 5 mM Ttis, pH 8.0. 
Binding was performed at 37°C for 1 h followed by a 4°C incubation over- 
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line (TBS), pH 7.5. Wells were incubated with culture supematants for 2 h 
at 37°C, washed three times with TBS containing 0.5% Tween 20. Wells 
were incubated with goat anti-mouse IgG/IgM conjugated to alkaline phos- 
phatase (Boehringer Marmheim Biochemicals, Indianapolis, IN) for 1 h at 
37°C, washed three times, then incubated for 1 h at 37"C with p-nitrophenyl 
phosphate (Sigma Chemical Co., St. Louis, MO). Absorbance at 405 nm 
was quantitated with a Titertek Multiskan microELISA reader. 
Positive hybridomas were subcloned by limiting solution. Ascites fluid 
was generated in pristane (Aldrich Chemical Co., Milwaukee, WI) primed 
BALB/c mice. All mAbs reported here are IgG1; mAbs C-4E5 and C-10B2 
have kappa light chains while C-6C1 and C-7H12 have lambda light chains. 
Antibodies were purified from ascites fluid by hydroxyapatite HPLC (Bio- 
Rad Laboratories, Richmond, CA). Antibodies were coupled to cyanogen 
bromide-activated Sepharose 4B as described by the manufacturer (Pharma- 
cia Fine Chemicals, Piscataway, NJ). mAb CVC-1 (6) was acquired from 
the American Type Culture Collection,  Rockville, MD (TIB 135). 
Sandwich ELISAs 
HPLC-purified mAbs were cross-linked to alkaline phosphatase in the fol- 
lowing manner. Antibody and alkaline phosphatase (bovine intestinal mu- 
cosa [Sigma Chemical Co.] were combined in PBS, pH 7.4, at 0.5 mg/ml 
each. The mixture was placed in a dialysis bag and dialyzed against a 500- 
fold excess volume of PBS containing 0.04% glutaraldehyde. After 8 h at 
4°C,  the  bag  was  moved  to  1,000-fold excess  volume  PBS  without 
glutaraldehyde and dialyzed overnight at 4"C. Samples were run through a 
Bio-Gel  P-200 column  equilibrated  with  PBS  containing  0.1% BSA. 
Colunm fractions were assayed directly by ELISA for CAP binding and en- 
zyme activity. 
PVC 96-well plates were incubated overnight at 4°C with 50 btg/rnl  puri- 
fied mAb in 5 mM Tris, pH 7.0. Plates were incubated the next day for 1 h 
at room temperature with  1%  BSA in 20 mM normal TBS, pH 7.5. The 
plates were washed with TBS containing 0.5% Tween 20 (TBS-Tween) and 
incubated overnight at 4°C with 25 Ixg/ml CAPs in TBS-Tween. The next 
day the plates were washed twice with TBS-Tween and incubated for 2 h 
at 37°C with 5 tag/ml alkaline phosphatase-eonjugated mAbs in 1% BSA 
in TBS. The plates were washed twice with TBS-Tween  and once with dis- 
tilled H20. Reactions were developed with p-nitrophenyl phosphate in 100 
mM glycine 1 mM MgCI2, 1 mM ZnCI2, pH 10.4. Color development was 
quantitated with a Titertek multiskan microELISA reader set at 405 nm. 
Chymotryptic Digests 
Chymotrypsin was dissolved first in 50 mM Tris,  10 mM MgCI2, pH 7.5, 
at 1 mg/mi, then diluted to 1.7 lag/ml  in a 1 mg/ml CCV preparation in 100 
mM morpholinnethanesulfonic acid buffer, pH 6.5. Digestions were per- 
formed for 30 s-1 h at room temperature before being stopped with 1 mM 
phenylmethylsulfonyl fluoride. Samples were then spun at 100,000 g in an 
airfuge and pellets and supernatants were dissolved in Laemmli sample 
buffer. 
Radioiodination of CCVs and CAPs 
CCVs and  CAPs were radioiodinated using lactoperoxidase/glucose oxi- 
dase-coupled beads as described  (Bio-Rad Laboratories).  Before radio- 
iodination,  CCVs and  CAPs were exhaustively dialyzed against pH 6.5 
phosphate buffer. Subsequent to radioiodination, CCVs and CAPs were re- 
suspended in 20 mM Hepes (Sigma Chemical Co.), pH 7.0, 1% BSA, 100 
mM  sodium chloride,  0.01% sodium azide,  and were purified twice by 
Sepharose 4B column chromatography. 
Phosphorylation of CAPS 
Pbosphorylation of CCVs was conducted in 100 mM Tris, 10 mM MgCl2, 
100 mM morpholinoethanesulfonic acid, pH 7.5. Reaction mixtures (100 ~l) 
contained 0.1  mg of CCVs, 20  I.tM ATP, and  1 I.tCi "t-32p-labeled ATE 
Some samples were supplemented by 50 ~g/ml poly-L-lysine 04 kD; Sigma 
Chemical Co.).  Incubations were performed for 10 min at room tempera- 
ture. Samples were heated at 100*C for 5 rain and spun at 100,000 g for I h 
before immunoprecipitation. 
lmmunoprecipitation of  CCVs and CAPs 
Radioiodinated CCVs, CAPs, and phosphorylated  CAPs were incubated 
with Sepharose 4B-coupled mAbs in Hepes, pH 7.0, containing 1% BSA, 
100 mM sodium chloride, and 0.01% sodium azide. A typical experiment 
consisted of  50 I.tl of  5 % Sepharose 4B incubated with either 100 I.tg of  unla- 
beled CAPs or 106 cpm of radioiodinated CAPs or CCVs. After incubating 
overnight at 4°C with agitation, the beads were pelleted briefly in a cen- 
trifuge (3200; Brinkmann Instruments Co., Westbury, NY), washed three 
times with 500 ~tl of 20 mM Hepes, pH 7.0, 1% BSA, then twice with 500 
I.tl of 20 mM Hepes, pH Z0, containing 100 mM sodium chloride. Samples 
were dissociated in Laemmli sample buffer (0.1% SDS, 50 mM Tris, pH 
6.5, 100 mM dithiothreitol,  10% glycerol) and counted. 
Gel Electrophoresis and Immunoblotting 
SDS PAGE was performed as described by Laemmli (7). Gels were stained 
with Coomassie Brilliant Blue and/or dried and autoradiographed using a 
Cronex lightening plus intensifying screen and Cronex x-ray film (Dupont 
Co., Wilmington, DE). 
Proteins were electrophoretically  transferred to nitrocellulose using a 
transfer apparatus (Bio-Rad Laboratories) and the procedure described by 
the manufacturer. Nitrocellulose filters were fixed, then saturated with 0.1% 
BSA and 0.05% Tween  20 in TBS, pH 7.5. Filters were incubated at 4°C 
overnight with primary  antibodies suspended in TBS, pH 7.5, containing 
0.1% BSA and 0.05% Tween 20. Filters were washed three times with TBS 
containing 0.05% Tween,  then  incubated  1 h  at 4°C  with  peroxidase- 
conjugated goat anti-mouse IgG/IgM  (Boehringer Mannheim Biochemi- 
cals) diluted in TBS containing 0.1% BSA and 0.05% Tween 20. After three 
washes with TBS containing 0.05% Tween 20 and one wash with 20 mM 
Tris, 0.5 M NaCI, pH 7.5, reactive bands were visualized with 4-chloro-1- 
naphthol (Bio-Rad Laboratories) and 0.015% hydrogen peroxide. 
Results 
Four Epitopes of CAP2 
Four unique mAbs to CAP2 were eventually generated from 
the fusion of immune BALB/c splenocytes to Sp2/0 myeloma 
cells. Two of  them, mAbs C-7H12 and C-6C1, were produced 
from a BALB/c mouse immunized with CAPs isolated from 
CCVs by heating at 100°C for 5 min, while mAbs C-10B2 and 
C-4E5 were produced from a mouse immunized with whole 
clathrin. All four mAbs reacted with CAPs from both neu- 
ronal and nonneuronal sources (Figs.  1 and 2). To localize 
reactive  sites  of the  mAbs,  sandwich  ELISAs  were  per- 
formed with purified mAbs coupled to alkaline phosphatase. 
PVC plates were coated with a purified mAb, incubated with 
l~gure 1. Reactivity of mAbs C-6C1, C-4E5, CVC-1 (6), and C-10B2 
with bovine brain and adrenal CCVs. (Lanes A) Brain CCVs; (lanes 
B) adrenal CCVs; and (lanes C) brain CVs digested 40 min with 
chymotrypsin (as described in Fig. 2). (Lanes A', B', C') Coomas- 
sie Blue stain; (lanes A, B, C) immunoblots. The different mobili- 
ties of neuronal and nonneuronal CAPs are evident in A' and B'. 
The mAbs C-6C1  and CVC-I also reacted with some of the lower 
molecular mass fragments in lane C.  CF2,  18-kD  fragment; CF3, 
15-kD  fragment. 
The Journal of Cell Biology, Volume 104, 1987  898 Figure 2. Reactivity of mAb C-7H12 with chymotryptic fragments of CAPs bound to clathrin heavy chains. CCVs, reassembled clathrin 
cages, reassembled cages containing only CAP2 and purified CAPs (total protein concentrations: 1 mg/ml in 100 mM morpholinoethane- 
sulfonic acid buffer, pH 6.5) were incubated with 1.7 Ig/ml chymotrypsin for various time periods, treated with phenylmethylsulfonyl fluo- 
ride, pelleted at 100,000 g in an airfuge (except the purified CAPs) and analyzed by SDS PAGE and immunoblotting with mAb C-7H12. 
(a) Coomassie stain of digested CCVs; (b) immunoblot of gel loaded as in a, using mAb C-7H12; (c) immunoblot using mAb C-7H12 of 
chymotryptically digested cages containing only CAP2; (d) immunoblot using mAb C-7H12 of chymotryptically digested cages containing 
both CAPt and CAP2; (e) immunoblot using mAb C-7H12 of chymotrypticaUy  digested free CAPs. In d and e CAP~ was obscured by CAPz 
reactivity, a and b were run using 7-15% gradient gels, which allowed greater separation of the CAPS than the 8-16% gels used in c-e. 
a preparation of  both CAPs, and subsequently incubated with 
a purified mAb coupled to alkaline phosphatase. The results 
of these experiments are summarized by the matrix in Table 
I. All of the mAbs completely inhibited themselves in the as- 
say but only variably inhibited each other. The mechanics of 
the sandwich ELISA prevent varying affinities of mAbs from 
affecting interpretation of the results. In other words, if the 
plate-bound antibody has a higher affinity for the same epi- 
tope as the competing antibody, the competing antibody will 
not bind and no reaction will be observed. If the opposite is 
true, the competing antibody will displace the bound CAP 
into solution and again no reaction will be observed in the 
solid phase.  Therefore, the results of the sandwich ELISA 
matrix indicate that binding sites of mAbs C-7H12,  C-6C1, 
C-10B2,  and  C-4E5  are  distinct.  The  epitopes  bound  by 
C-7H12 and C-6C1  may be situated in the same domain of 
the CAP molecule and this would explain their partial inhibi- 
tion in the sandwich ELISA. Similar results were obtained 
for mAbs  C-10B2  and C-4E5,  which completely inhibited 
themselves but  only partially  inhibited  each other in  the 
sandwich ELISA. 
Close inspection of the sandwich ELISA matrix revealed 
that plate-bound mAbs C-7H12 and C-6C1 appear to slightly 
reduce binding by mAbs C-4E5 and C-10B2. The reciprocal 
experiments using  plate-bound mAbs  C-4E5 and  C-10B2, 
however,  did  not  reveal  significantly reduced  binding  by 
C-6C1  or C-7H12. The inhibition may be attributed to bind- 
ing of  both CAPs by C-7H12 and C-6C1, which competitively 
reduces the binding of C-4E5 and C-10B2,  which bind only 
CAP2.  This effect is not observed in the reciprocal experi- 
ment inasmuch as C-7H12 and C-6C1 efficiently bind CAP2 
sandwiched by either C-10B2 or C-4E5 
Assigning mAb Binding Sites to Chymotryptic 
Fragments of CAPs 
To characterize the reactive sites of each mAb on the CAP 
molecule,  CCVs  were  chymotryptically digested  and  the 
vesicle-bound proteolytic fragments were isolated by cen- 
trifugation and subsequently analyzed by SDS PAGE and im- 
munoblot. By varying the digestion times, CAP fragments 
were generated that were trimmed increasingly close to the 
heavy chain binding site. Immunoblotting experiments using 
these fragments and the anti-CAP mAbs facilitated construc- 
tion of a cleavage map of the CAPs using the clathrin binding 
site as a reference point. 
Fig. 2 a  shows chymotryptic fragments that were gener- 
ated when CCVs were used as substrate. Fig. 2 b is an immu- 
noblot of an identically loaded gel using mAb C-7H12.  For 
convenience, we have divided the CAP fragments into two 
categories:  fragments common to  CCVs  and  reassembled 
cages (CFs) and unique fragments. The CFs consist of 30-kD 
(CF0,  18-kD  (CF2),  and  15-kD  (CF3)  fragments. Previous 
experiments (8,  9) have shown that CF2 and  CF3  are  pro- 
Table L  Sandwich ELISA of Anti-CAP2 mAbs 
Soluble alkaline phosphatase-conjugated mAbs 
Coated 
mAb  C-7H 12  C- 10B2  C-6(21  C-4E5 
C-7H12  -  ++  +  ++ 
C-10B2  +++  -  +++  + 
C-6C1  +  +++  -  ++ 
C4E5  +++  +  ++  - 
CAPs  +++  +++  +++  +++ 
Purified mAbs were coated on PVC plates, incubated with CAPs, and subse- 
quently incubated with alkaline phosphatase-conjugated mAbs. Reactivity was 
quantitated colorimetricaUy using p-nitrophenyl phosphate.  Results represent 
the mean of three data points in a  typical experiment. The  concentration of 
plate-bound CAPs (last row) was adjusted  stoichiometrically to 40%  of the 
amount of plate-bound antibody. Coupled antibodies were titered to produce 
an OD at 405 nm of 1-1.5 after 1 h. A control value using an unrelated alkaline 
phosphatase-conjugated IgG1 murine mAb was determined for each row, and 
subtracted to give the reported results. 
+ +  +  66-100%  of absorbance using PVC plate-bound CAPs. 
+ +  65-32%  of absorbance using PVC plate-bound CAPs. 
+  10-32%  of absorbanee using PVC plate-bound CAPs. 
-  <10%  of absorbance using PVC plate-bound CAPs. 
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Figure  3. Reactivity of anti-CAP mAbs with free and clathrin heavy 
chain-bound  CAPs.  ELISAs  were performed  using  PVC  plates 
coated with either  free CAPS (a)  or clathrin-bound CAPs (b). 
Purified mAbs, at various concentrations, were used and bound 
mAb was  quantitated using an alkaline phosphatase-conjugated 
second antibody. 
duced by chymotryptic digestion of either CCVs or reassem- 
bled clathrin cages. We show in Fig. 2 that CF1 can also be 
generated from either structure. 
To determine which fragments are generated from CAPt 
and which are generated from CAPE, clathrin cages were 
stripped of CAPs with sodium isothiocyanate as described 
(14),  and  reassociated  with  mAb  C-4E5  afffinity-purified 
CAPE. The reassembled cages were digested with chymo- 
trypsin as before and blotted with mAb C-7H12. As shown 
in Fig. 2, c and d, CF~ and CF3 are produced by cages con- 
taining only CAPE; hence these fragments must be gener- 
ated by proteolysis of CAPE, while CFE must be generated 
from CAP~. These results support the notion that CAP~ and 
CAP2  bind  clathrin  with  structurally  similar  domains 
shared by both proteins. Interestingly, CVC-1 (6) also binds 
CFE (Fig.  1), confirming its identity as a fragment of CAP1. 
CVC-1 (6) does not react with CAPE, CF3,  or  CFt,  but it 
does react with clathrin-bound CAP~. These data indicate 
that  CF2  contains  at  least  two  distinct  epitopes:  one  is 
shared by CAP2 and appears to be involved in clathrin bind- 
ing; the other is unique to CAP~. 
Several  CAP  fragments  are  generated  with  molecular 
masses <10 kD using either CCVs or reassembled cages as 
substrates. The common fragments in this range are difficult 
to identify, although CCVs appear to produce a smaller set 
of fragments than reassembled cages. This implies that CAPs 
are less  accessible in CCVs  than they are in reassembled 
cages, which is not surprising considering the more complex 
structure of the vesicle. The small size of unique fragments 
generated from either reassembled cages or CCVs has led us 
to  suggest that mAb  C-7H12 binds  an epitope involved in 
Figure 4. Fraction of total radioiodinated CCVs or radioiodinated 
CAPs precipitated by anti-CAP mAbs coupled to Sepharose 4B. 
The mAbs used were at l@-fold  excess over the amount needed to 
precipitate an equivalent mass of  unlabeled CAPs. Iodination of  free 
CAPs variably affected the efficiency of immunoprecipitation by 
each mAb. 
clathrin heavy chain binding. Unless this epitope constitutes 
a linear string of amino acids, structural conservation of this 
region of the molecules may not be obvious from primary se- 
quence analysis (3). 
Anti-CAP reactivity was not detected in supernatants of 
chymotryptic digestion experiments using C-10B2,  C-4E5, 
or anti-CAP1  mAb CVC-1 (6; data not shown).  Either the 
released fragments are digested beyond recognition by these 
mAbs or the reactive epitopes span residues on both released 
and bound fragments. CAPs isolated by boiling and digested 
with chymotrypsin produce a plethora of new fragments in 
addition to CF~,  CFE,  and CF3 (Fig.  2 e). Hence, binding 
by clathrin affords considerable protection against proteoly- 
sis by chymotrypsin. 
Monoclonal Antibody 7H12  Reacts with the 
Clathrin-binding  region of  both CAPs 
The immunoblot in Fig. 2 b shows that mAb C-7H12 reacts 
with both CAPs. Until now, all reported mAbs have reacted 
specifically with one of the CAPs (6). The existence of cross- 
reactive epitopes may be predicted, however, from the bio- 
chemical characteristics of the proteins. In particular, both 
CAPs appear to bind a common site on the clathrin heavy 
chain (14). This implies that the clathrin-binding regions of 
both CAPs share structural homology, and antibodies to this 
region of the molecules should cross-react with both forms. 
With these considerations in mind, an ELISA was used to de- 
termine the relative reactivity of each of the mAbs with free 
CAPs and clathrin-bound CAPs. Fig. 3 shows mAbs CVC-1 
(6), C-4E5, C-10B2,  C-6C1, and C-7H12 reacting with free 
CAPs. On the other hand, only mAbs CVC-1 (6), C-4E5, and 
C-10B2 react with the clathrin-bound CAPs present in puri- 
fied preparations of triskelions,  mAb C-6C1  reacts poorly 
with clathrin-bound CAPs, while mAb C-7H12 does not react 
with clathrin-bound CAPs. These results were obtained only 
when the clathrin-bound CAPs were pre-spun as cages or 
CCVs before coating on PVC plates.  CAPs apparently dis- 
sociate from clathrin at a  slow rate during storage at 4°C. 
To document further the lack of reactivity of mAb C-7H12 
with  clathrin-bound  CAPs,  immunoprecipitation  experi- 
ments were performed using radioiodinated CCVs and radio- 
iodinated free CAPs. Purified mAbs C-7H12, C-10BE, CVC-1 
(6),  and  C-4E5  covalently coupled to Sepharose 4B were 
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suspended in phosphorylation buffer containing 50 ttg/ml polyly- 
sine and 1 la2i y-32p-labeled  ATP in 20 ttM ATP. After a 10-min 
incubation at room temperature, samples were heated at 100°C for 
5 rain, denatured proteins pelleted,  and supernatants either ana- 
lyzed directly by SDS PAGE (lane A), or immunoprecipitated by 
anti-CAP1 mAb CVC-1 coupled to Sepharose 4B beads. (lane B) 
5 ttl of a 10% solution of coupled beads; (lane C) 10 ttl; (lane D) 
20 ttl. The bands of lower molecular mass represent the kappa light 
chains  of the  immunoglobulins. (Lanes A-D)  Coomassie  Blue 
stains; (lanes A'-D') autoradiography. 
used for these experiments. These mAbs precipitate radioio- 
dinated free CAPs with varying efficiencies (Fig. 4).  mAb 
C-7H12,  however, does not precipitate detectable counts of 
radioiodinated CCVs.  This indicates that in the conforma- 
tion present on the CCVs, CAPs are not recognized by mAb 
C-7H12,  but are recognized by mAbs CVC-1, C-10B2,  and 
C-4E5. These results differ from those reported recently (2) 
in which mAbs to CAP1 were only shown to be hindered 
from binding the clathrin-CAP complex. In total, our data 
suggest that mAb C-7H12 reacts directly with the clathrin- 
binding sites shared by both CAPs. 
Mapping the CAP Phosphorylation Site to 
Accessible End of CAP2 
A  kinase activity recently has been associated with CAP2 
(12, 13). This activity was recently confirmed in another re- 
port and attributed to an endogenous CCV casein kinase II 
(1). Although this activity is intensified by polybasic com- 
pounds such as polylysine or histone 1 (12), phosphorylation 
can be detected in the absence of these compounds by immu- 
noprecipitation and long-term automdiography (Kohtz, D. S., 
and S.  Puszkin, unpublished results).  A  significant feature 
of this phosphorylation is its substrate preference for CAP2 
(12).  Nevertheless, phosphorylation of CAP1 was detected 
in the presence of  polylysine after radioimmune precipitation 
with anti-CAPl mAb CVC-1 (6) and long-term autoradiog- 
raphy (Fig. 5). Whether phosphorylation sites are partially 
conserved between  the  two  forms  of CAP  is  unclear  at 
present. 
An ELISA was devised to determine how efficiently phos- 
phorylated CAPs react with each of the mAbs in comparison 
to unphosphorylated CAPs. PVC plates were coated with un- 
phosphorylated CAPs.  The titer of purified mAb  was ad- 
justed in preliminary experiments to produce an optical den- 
sity of 2 at 405 nm after 2 h of incubation (using a  1:1000 
dilution  of alkaline  phosphatase-conjugated  second  anti- 
body; Boehringer Mannheim Biochemicals). Purified mAbs 
at this dilution were preincubated with varying amounts of 
Table II. Competitive ELISA Using Phosphorylated 
and Unphosphorylated CAPs 
Antibody (absorbance  405 nm 
[PO4-CAP/CAP]) 
PO4-CAP 
or CAP  C-4E5  C-10B2  C-7H12  C-6CI 
50  0.1/0.1  0.3/0.2  0.2/0.1  0.2/0.1 
25  0.2/0.2  0.6/0.5  0.5/0.4  0.5/0.5 
10  0.5/0.4  1.2/1.0  0.7/0.7  0.8/0.7 
5  1.1/1.0  1.5/1.3  1.1/1.1  1.2/1.1 
1  1.6/1.5  1.8/1.6  1.3/1.2  1.4/1.3 
0.5  1.7/1.6  1.8/1.8  1.6/1.6  1.7/1.6 
0.1  1.9/1.9  1.9/1.9+  1.8/1.8  1.9/1.8 
0  1.8/1.9+  1.9/1.9+  1.9/1.9  1.9+/1.9 
PVC plates were coated with unphosphorylated CAPs, then incubated with 
mAbs in the presence of the indicated amount of phosphorylated or unphos- 
phorylated CAPs (phosphorylated/unphosphorylated). Binding was quantitated 
using an alkaline phosphatase-conjugated  anti-mouse second antibody. Results 
represent the means of three values from a typical experiment. A control value 
using an unrelated IgG1  murine mAb was determined for each row, and sub- 
tracted to give the reported results. 
either  phosphorylated or  unphosphorylated  CAPs.  These 
preparations  were  subsequently  incubated  with  the  PVC 
plate-bound CAPs, and bound antibody was quantitated with 
the alkaline phosphatase-conjugated anti-mouse second an- 
tibody.  As  shown  in  Table  II,  phosphorylated  and  un- 
phosphorylated CAPs bind almost equally well to all of the 
mAbs.  Phosphorylated CAPs do not appear to compete as 
well for mAb C-10B2 as unphosphorylated CAPs, although 
the difference is small.  The similar affinities of phosphor- 
ylated and unphosphorylated CAPs for all the mAbs is also 
reflected in the efficiency of immunoprecipitation of phos- 
phorylated CAPs.  CAP2 was phosphorylated by the CCV- 
associated kinase activity in the presence of polylysine. The 
samples were heated, denatured proteins removed by cen- 
trifugation, and the CAPs precipitated with mAbs coupled to 
Sepharose 4B. Since the beads were coupled to equal amounts 
of purified antibody, we assumed that their specific binding 
activities  were  equivalent.  The  autoradiograph  in  Fig.  8 
shows that mAbs C-10B2, C-4E5, and C-7H12 all precipitate 
phosphorylated CAPs in a quantitative manner. Interestingly, 
a doublet was precipitated by C-10B2.  Using a limited con- 
centration  of CAPs  and  varying  the  proportion of phos- 
phorylated CAP2 also does not appear to quantitatively af- 
fect the efficiency of CAP2 immunoprecipitation by any of 
the mAbs (Fig. 6). 
To determine whether any of the mAbs reacted with epi- 
topes relevant to the phosphorylation process, kinase inhibi- 
tion experiments were performed (Fig. 7). For this, mAbs 
at 3.5-fold molar excess to CAP2 were incubated with CCVs 
in phosphorylation buffer overnight at 4°C. Polylysine and 
gamma radiolabeled ATP were added and the reactions were 
stopped at various time points with EDTA.  Samples were 
heated to  100°C for 10 rain and pelleted. The supernatants 
were analyzed by SDS PAGE and autoradiography. None of 
the mAbs inhibited phosphorylation of casein by the endoge- 
nous CCV  casein kinase II (data not shown).  Both mAbs 
C-4E5  and C-10B2  inhibited phosphorylation of CAP2 for 
as long as 5 min after the addition of  ATP. The inhibition pro- 
files of these mAbs appear to differ slightly.  CCVs  prein- 
cubated  with  C-10B2  rapidly  acquire  a  small  amount  of 
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phorylated and unphosphorylated CAPs by mAbs C-10B2, C-4E5, 
and  C-7H12. A  limiting titer of coupled  antibody was  used  to 
precipitate a total of 20 Ixg of CAP2. The various amounts of phos- 
phorylated CAP2 in the total amount are indicated in micrograms. 
Were phosphorylated CAP2 precipitated less efficiently than un- 
phosphorylated CAP2, the total precipitated protein would be re- 
duced as the proportion of phosphorylated CAP2 increased. The 
lower molecular mass bands are antibody light chains, which ap- 
parently do not couple efficiently  and are released in Laemmli sam- 
ple buffer containing dithiothreitol. Arrow indicates CAPx precipi- 
tated by mAb C-10B2. 
CAP2-bound phosphate before being completely inhibited, 
while CCVs  preincubated with C-4E5  slowly but progres- 
sively acquire CAP2-bound phosphate. The pattern of inhi- 
bition produced by mAb C-4E5 could be interpreted as less 
complete than that produced by mAb C-10B2. This would re- 
sult from differences in affinity between the two mAbs, or 
differences in the proximity of the antigenic sites to the phos- 
phorylation site.  Alternatively, since it has been suggested 
that CAP2 contains more than one phosphorylation site (12), 
the  antibodies  may  be  inhibiting  the  phosphorylation of 
different residues. Further experiments are in progress to de- 
termine which of these possibilities is valid (Kohtz, D.  S., 
W. J.  Schook, and S. Puszkin, manuscript in preparation). 
A  32-kD Phosphoprotein Cross-reacts 
with Anti-CAPz mAb C-10B2 
Curiously, mAb C-10B2 coprecipitates another heat-stable, 
32-kD phosphoprotein from the CCV preparation. As indi- 
cated by the open arrow on the autoradiography in Fig. 8, the 
coprecipitated phosphoprotein migrates immediately below 
the phosphorylated CAPE. This phosphoprotein apparently 
competes very effectively with CAP2 for mAb C-10B2, since 
it is not detectable in preparations of total CAPs (e.g., Fig. 5, 
lanes A  and A').  In  C-10B2  precipitate,  the  32-kD  phos- 
phoprotein is  substantially enriched,  indicating an affinity 
for mAb C-10B2 at least as high as that of CAP2; this is ap- 
parent  in  both  the  autoradiograph  in  Fig.  8  and  in  the 
Coomassie stain in Fig.  6  (indicated by arrow). 
The 32-kD protein does not react with mAbs reactive with 
CAP~  nor  with  mAbs  reactive  with  DARPP  32  (kindly 
provided by Dr. P. Greengard, Rockefeller University, New 
York). Also, it only reacts with one of the four mAbs recog- 
nizing CAPE (although traces may be present in mAb C-4E5 
precipitates, not shown), implying that it is not a proteolytic 
fragment of this protein.  We have tentatively labeled this 
phosphoprotein CAPx (or LCx), and are presently determin- 
ing whether it is a CCV component or a soluble contaminant 
of  our preparations. Its stability during heat denaturation (the 
vesicles  are  heated and  centrifuged before precipitation), 
phosphorylation properties (it is phosphorylated in the pres- 
ence of polylysine), and cross-reactivity with an anti-CAP2 
mAb (C-10B2) indicate that it may be structurally related to 
CAP2. 
Discussion 
The characterization of mAbs to CAPs by our laboratory and 
others (2, 6) has revealed considerable structural diversity 
between the two forms (CAPI  and CAP2).  The functional 
significance of  this diversity is probably relevant to the evolu- 
tion of higher organisms, since yeast appear to possess only 
one  form  of CAP.  At  present,  the  explicit  functions  as- 
sociated with this diversity have evaded elucidation. Instead, 
two properties mediated equally well by both forms of CAPs 
have been described:  (a) an ATP-dependent uncoating en- 
zyme works by initially binding to either of the CAP mole- 
cules (11), and (b) a single site on the clathrin heavy chain 
binds equally well to either form of CAP (14). Hence, mAbs 
that distinguish the two forms of CAPs would not be as likely 
to recognize epitopes involved in these conserved functions 
as mAbs reacting with both CAPs. 
In  this  report,  two  mAbs  (C-6C1  and  C-7H12)  are 
presented that react with epitopes shared by both CAPs. The 
term "conserved domain" may be used to describe the struc- 
tural  region of the  CAPs  reactive with  these mAbs.  The 
significance of the epitope recognized by C-6C1 has not been 
detailed,  although chymotryptic mapping  experiments re- 
Figure 7. Autoradiography showing the inhibition of CAP2 phosphorylation by mAb C-10B2 and C-4E5. mAbs at 3.5-fold molar excess 
to CAPs were preincubated with CCVs overnight at 4°C. Time periods for the phosphorylation reaction ranged from 1 to 6 min. Reactions 
were stopped by adding 250 mM EDTA  (1:10, pH 8.0), heating to 100°C for 10 min, and pelleting. Supernatants were analyzed by SDS PAGE. 
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by mAbs coupled to Sepharose 4B. CCVs were phosphorylated in 
the presence of polylysine, heated at 100°C for 5 rain and pelleted. 
Aliquots of supernatant  from a  single phosphorylation  reaction 
were immunoprecipitated by various volumes (in microliters) of a 
10% solution of Sepharose 4B-coupled mAbs. Approximately 1 ~g 
of mAb is bound per I~l of 10 % Sepharose 4B suspension. Precipi- 
tates were dissociated with Laemmli sample buffer and analyzed by 
SDS PAGE and autoradiography. 
vealed that it is near the clathrin-binding region of the CAPs. 
The mAb C-7H12 appears to react with an epitope directly 
on the clathrin-binding domain as evidenced by chymotryp- 
tic mapping,  ELISAs using clathrin-bound CAPs and free 
CAPs,  and  immunoprecipitation experiments using  radio- 
iodinated CCVs and CAPs. Sandwich ELISAs indicate that, 
despite their proximity, the epitopes recognized by mAbs 
C-6C1  and C-7H12 are distinct. 
We describe elsewhere two mAbs  (C-10B2  and  C-4E5) 
reactive specifically with CAP2 (Kohtz, D. S., J.  D. Kohtz, 
W. J. Schook, and S. Puszkin, manuscript submitted for pub- 
lication).  Sandwich  ELISAs  indicate  that  mAbs  C-10B2, 
C-4E5,  C-7H12 and C-6C1  react with distinct epitopes on 
CAPE. As may be inferred from the degree of sterically in- 
duced inhibition observed in these assays, mAbs C-10B2 and 
C-4E5 appear to react with different epitopes in the same re- 
gion of CAPE. As judged by its sensitivity to chymotryptic 
digestion, this region of CAPE is on an accessible end of the 
molecule. The term "nonconserved domain" may be used to 
refer to this  accessible edge of the CAP2  and  its putative 
counterpart on CAPI. 
Two kinase activities are associated with CCVs. The first 
is  CaE+/calmodulin -  and cAMP-independent,  and uses the 
50-kD assembly complex polypeptide as a substrate; the sec- 
ond is accentuated by the presence of polybasic compounds 
and uses CAPE as a substrate. Direct inhibition experiments 
indicate that mAb C-10B2 and C-4E5 react with an epitope 
relevant to the phosphorylation process. In particular, C-4E5 
inhibits phosphorylation better in the short run while C-lOB2 
inhibits  better  in  the  long run.  Inhibition of CAPE phos- 
phorylation by these mAbs  could be produced by several 
mechanisms:  steric interference of the bound antibody and 
the  enzyme;  allosteric  structural  alterations  produced  in 
CAPs by bound antibody; direct competition for the enzyme 
binding site by the antibody; and,  if it is distinct from the 
enzyme-binding site, direct blocking of the phosphorylation 
site by bound antibody. Further work is necessary to deter- 
mine  the  mechanisms  responsible  for inhibition of CAPE 
phosphorylation by each mAb. 
Immunoprecipitation experiments using mAb C-10B2 re- 
vealed a  cross-reactive phosphoprotein with  a  molecular 
mass of 32 kD. We referred to this phosphoprotein as CAPx 
or LCx, since it coprecipitates with CAPE. This polypeptide 
is not coprecipitated by C-4E5, CVC-1 (6), C-7H12, or C-6C1, 
indicating that it is not a  CAP fragment.  Since CAPx is a 
phosphoprotein and C-10B2  does inhibit CAP2 phosphory- 
lation,  it appears  that  C-10B2  cross-reacts with the phos- 
phorylated epitopes on both polypeptides. Similarities be- 
tween the polypeptides suggest that it is a  member of the 
CAP family. In particular, CAPx is heat stable, it can be iso- 
lated from CCV preparations, and it is phosphorylated under 
the same conditions as CAPE. When a  CAPx-specific anti- 
body is produced it may be possible to ascertain if the poly- 
peptide is an integral vesicle protein. 
Immunoprecipitation experiments using C-4E5 and CVC- 
1 (6) revealed two other properties of CAP phosphorylation. 
CAPE is phosphorylated in the absence of effectors, but to a 
considerably lesser degree;  and  CAP1 is  also phosphory- 
luted in the presence of polylysine, but not to the same extent 
as CAPE. The latter observation implies that the phosphory- 
lation process is not absolutely specific for CAPE, and in 
the presence of other mediators or enzymes, CAPl may be 
equally  well  phosphorylated.  Alternatively,  Usami  et  al. 
(13), have indicated that CAPE bears three sites of phosphor- 
ylation; CAP~ may have conserved only a fraction of these 
sites.  Further work should elucidate the physiological sig- 
nificance of each site of phosphorylation and their distribu- 
tion on each CAE 
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